Caution Advised With Upfront SGLT2 Inhibitor-MRA Combo for Heart Failure
Biomarker results mixed in small trial
Related Articles
Popular Diabetes Drugs Linked to Small Risk of Retinal, Optic Nerve Disorders
Screening, monitoring for eye disease urged for all patients on semaglutide, tirzepatide
Aluminum in Vaccines Study Won’t Be Retracted, Journal Says
Large Danish study evaluated risks of autism, asthma, and other disorders in 1.2 million children
Prophylactic Antibiotics May Be of No Use in Cirrhosis With Upper GI Bleeding
Findings contradict current guidelines, suggesting a need for new randomized trials
FDA Restricts Gene Therapy Skysona Due to Blood Cancer Risk
Treatment should be used only in CALD patients without suitable alternative options
Brain Autopsies Suggest MIND Diet Reduces Pathology
Diet-dementia relationship was partly mediated by hippocampal sclerosis, data suggest
Dariush Mozaffarian and Emily Callahan on Nutrition Support in GLP-1 Therapy
OMA has a new on the critical role of nutritional support for patients with obesity during treatment with glucagon-like peptide 1 receptor agonists (GLP-1s). The…
Deion Sanders’ Cancer Diagnosis: Here’s What to Know
‘Prime Time’ as patient: former NFL star, college football coach talks about his bladder tumor
Tirzepatide’s CV Benefit; PREVENT Age Calculator; Rectal Injection for BP Reduction?
Recent developments of interest in cardiovascular medicine
Nation’s IV Saline Shortage Is Over, FDA Declares
Shortage in part stemmed from hurricane damage to key North Carolina facility in 2024
KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer
Overall survival data still outstanding for adagrasib in KRAS G12C-mutated advanced NSCLC